MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-99
SponsorFox Chase Cancer Center
About this trial
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
Eligibility criteria
Qualifiers
Follicular Lymphoma (Grade 1-3a)
Marginal Zone Lymphoma
Lymphoplasmacytic Lymphoma
Age > 18 years
Disqualifiers
Radiation or systemic treatment for lymphoma within the past 28 days prior to cycle 1 day 1 of BR.
Patients with pathologically confirmed transformed lymphoma, including diffuse large B cell lymphoma or other high grade lymphomas
Patients on active treatment for second malignancy with the exception of endocrine therapy for non-metastatic breast cancer, hormone therapy for prostate cancer, or local treatment for non-melanoma skin cancer.
Pregnant or breast-feeding. Refer to section 5.4 for further detail.
Trial design
Treatments tested in this trial
- Bendamustine
- Rituximab
Treatment groups
24 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Fox Chase Cancer Center
Lead sponsor
Adaptive Biotechnologies
Collaborator
Source ClinicalTrials.gov